The proven safety of References for Flavay™ and Flavay Plus™

The rigorous testing to meet the standards required by the health ministries of France and other European countries demonstrate that Flavay™ is highly
bioavailable, nontoxic, nonallergenic, noncarcinogenic, nonmutagenic,
will not cause birth defects, and is completely safe.

After more than 50 years of human use, no adverse effects have been observed. Furthermore, intensive biological, toxicological, pharmacological and analytical research was conducted for the purpose of registering it as a medicine in France and other countries in Europe. In one study, daily doses of up to 35,000 mg for six months were determined to cause no adverse effects. Flavay™ was also clinically tested, in particular for all sorts of symptoms related to venolymphatic insufficiencies. The spin-off is a goldmine of data: The rigorous testing to meet the standards required by the health ministries of France, Germany and other European countries demonstrate that Flavay™ is highly bioavailable, nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth defects, and is completely safe.

Dr. Masquelier’s unequaled manufacturing process has been conducted for half a century at the very same facilities in France, and under the control of French Pharmaceutical inspection. These time-proven standards serve as a reliable assurance of the quality, consistency, bioavailability and safety of Flavay™.

Everyone, from the very young to the elderly. Flavay™ has no known contraindications (conditions under which it should not be used). Flavay™ is completely safe and nontoxic. In fact, clinical trials have been conducted in which pregnant women (troubled by varicose veins and other circulatory problems in the legs) safely used Flavay™.

Flavay™ may enhance the anticoagulant effects of anticoagulant drugs (such
as Coumadin or heparin). Notify your physician if you are taking
anticoagulant drugs, as a blood test may indicate to your physician that the
drug dose may be reduced if Flavay™or Flavay Plus™is being consumed. This
is because Flavay™ has been shown to normalize the reactivity ("stickiness")
of blood platelets. [More...]

The essential vitamins and minerals in Flavay Plus™ are naturally-derived and completely safe when used as directed on the label.

Flavay Plus™ includes phosphatidyl serine, derived from soy lecithin, which has been proven safe in standard toxicology tests. From the large number of human studies conducted, phosphatidyl serine has developed a flawless safety record and proven compatible with a wide array of medications.

Masquelier, J. Plant extract with a proanthocyanidins content as a therapeutic agent having radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
Kidd, P.M. Phosphatidylserine: the nutrient that accelerates all brain functions and counters Alzheimer’s disease: Keats Pub. 1998.
Cenacchi T, et al. Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging, 5: 123–133, 1993.
Maggioni M, Picotti GB, Bondiolotti GP et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 81: 265–270, 1990.
Brambilla, F., Maggioni, M., Panerai, A.E., et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients—effects of phosphatidylserine therapy. Neuropsychobiology, 34: 18–21, 1996.
Monteleone P., Maj M., Beinat L., Natale M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm, 43: 385–388, 1992.
Cenacchi T, et al., “Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.” Aging, 5, 123-133, 1993
Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger, G. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res, 317:1235-46, 1989.
Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., Schatzberg, F.A. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. Journal of the Amer Med Assoc, 278 (16):1327-32, 1997.